-+ 0.00%
-+ 0.00%
-+ 0.00%

Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia

Barchart·12/10/2025 07:52:00
Listen to the news

ORLANDO, Fla., Dec. 10, 2025 /PRNewswire/ -- New data from a dose‑intensive regimen of Cellenkos' CK0804 regulatory T cells (Tregs) in patients with myelofibrosis who had an inadequate response to standard-of-care therapy were presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida (Abstract #5602).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.